- Citi analyst Christopher Danely spent the last few weeks meeting with clients across the country and wanted to express his thoughts on sentiment and stocks.
- He remained negative on semis but believed a short-term rally could continue through August, given near-term downside is understood. Investors were universally bearish on semis, but a large-scale collapse was not imminent.
- He launched cheerful catalyst watches on NXP Semiconductors NV (NASDAQ:NXPI) and ON Semiconductor Corp (NASDAQ:ON) in anticipation of good earnings and a short-term bounce in the group and a negative catalyst watch on Intel Corp (NASDAQ: INTC) due to downside to estimates for earnings.
- Previously, Citi reiterated Neutral on Intel Corp INTC and Advanced Micro Devices, Inc (NASDAQ:AMD), betting on a contraction in the PC market to impact both negatively.
- May marked the fifth consecutive month where notebook shipments were below expectations.
- It cut the 2Q22E notebook shipments from down 3% Q/Q to down 11% Q/Q, well below seasonality of up 5%-10% Q/Q.
- Intel reportedly looks to hike its processor prices after Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM). It could force PC vendors to opt for advance purchases.
- Rising production costs put pressure on chipmakers amid demand slowdown for smartphones and personal computers on market uncertainties fueled by inflation, the Ukraine crisis, and COVID-related lockdowns in China.
- Photo by jonas-svidras via Unsplash
Ionis Partner Roche Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 clinical study in patients with immunoglobulin A nephropathy (IgAN).
